CS
GRNA

Credit Suisse’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Credit Suisse’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-34,719
Closed -$41K – 3888
2022
Q4 		$41K Buy
34,719
+1,854
+6% +$3.02K ﹤0.01% 3424
2022
Q3 		$76K Buy
32,865
+394
+1% +$1.03K ﹤0.01% 3488
2022
Q2 		$72K Buy
+32,471
New +$225K ﹤0.01% 3585

Other funds holding GRNA

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CGC
Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

Credit Suisse's GRNA Position: Q1 2023 in Review

Credit Suisse sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q1 2023, closing a stake of 34,719 shares — an estimated $41K sold.

Credit Suisse first reported a position in GRNA in Q2 2022 and held it in 3 quarters. The position peaked at $76K in Q3 2022. 60 funds tracked by Wall St. Rank hold GRNA as of Q1 2023.

  • Credit Suisse reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 34,719 GreenLight Biosciences Holdings, PBC Common Stock shares in Q1 2023, an estimated $41K.
  • Credit Suisse first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $76K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.